1. Australia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Clover Corporation Limited

Clover Corporation Limited

AASX:CLV
1.02
AUD
+0.00
(-0.49%)
0.04EPS
13.21P/E
92.68MMarket Cap
Mar 16Next Earn
Clover Corporation Limited
ASX:CLV
(Australian Securities Exchange)

Recent

price

1.02

P/E

ratio

13.21

div

yld

1.47%

ROIC.AI

2009
2010
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AUD
0.13
0.21
0.23
0.27
0.16
0.18
0.26
0.29
0.38
0.46
0.53
0.36
0.42
0.48
0.37
0.51
Revenue per Share
0.02
-0.01
0.03
0.04
0.01
- -
0.01
0.02
0.05
0.06
0.08
0.04
0.04
0.04
0.01
0.04
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
0.01
0.01
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.02
0.02
0.03
0.01
0.02
0.01
0.02
Dividend per Share
0.17
0.16
0.18
0.2
0.18
0.18
0.18
0.2
0.23
0.27
0.35
0.35
0.38
0.4
0.4
0.43
Book Value per Share
0.15
0.13
0.16
0.17
0.16
0.15
0.17
0.19
0.22
0.26
0.33
0.34
0.37
0.39
0.39
0.42
Tangible Book Value per Share
165
165
165
165
165
165
165
165
165
165
166
166
166
167
167
167
Basic Weighted Avg Shares
21
35
38
44
27
30
43
48
63
77
88
61
71
80
62
86
Sales/Revenue/Turnover
13.58
17.53
17.65
16.32
2.91
-2.42
5.59
10.28
14.69
17.18
20.03
14.57
14.72
10.47
3.16
9.69
Operating Margin (%)
- -
- -
1
- -
- -
1
- -
1
1
- -
1
1
1
1
1
2
Depreciation Expense
3
-1
4
6
1
- -
2
4
8
10
12
6
7
6
2
7
Net Income, GAAP
31.02
161.71
31.24
28.59
21.51
- -
28.8
27.39
28.52
27.66
29.28
26.56
27.51
25.79
20.97
32.78
Effective Tax Rate (%)
14.59
-2.77
11.39
13.78
3.56
0.33
5.16
7.6
12.05
13.17
14.14
9.92
10.09
7.77
2.44
8.16
Profit Margin (%)
30
33
41
43
39
20
24
28
33
38
48
47
50
52
47
46
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
4
12
13
12
10
10
7
1
LT Debt
28
26
30
32
30
29
30
33
38
45
58
58
63
67
67
72
Total Equity
7
-3.07
16.34
16.38
1.98
- -
5.69
11.34
17.21
18.12
18.62
8.9
10.14
7.98
1.98
7.24
Return on Invested Capital (%)
11.16
-3.59
15.66
19.42
3.09
- -
7.43
11.59
20.26
20.49
19.73
8.7
10.1
8.76
2.85
9.44
Return on Capital (%)
11.16
-3.59
15.74
19.51
3.09
0.34
7.43
11.59
21.46
24.26
24.32
10.35
11.75
9.53
2.26
10.07
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.71%
4.7%
7.7%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
258.4%
48.27%
363.04%
Sales/Revenue/Turnover
13.79%
2.9%
38.25%
Total Cash Common Dividend
- -
24.62%
100.08%

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
80
2024
- -
- -
62
2025
- -
- -
86

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.04
2024
- -
- -
0.01
2025
- -
- -
0.04

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.02
2024
- -
- -
0.01
2025
- -
- -
0.02
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Clover Corporation Limited engages in the refining and sale of natural oils, production of encapsulated powders, and research and product development of functional food and infant nutrition ingredients using proprietary microencapsulation technology for nutritional oils including tuna, fish, algal and fungal sources. The company offers core products such as Nu-Mega Hi-DHA tuna oils and Driphorm microencapsulated powders with Hi-DHA tuna and algal oils; Ocean Gold refined tuna oils; CholineXcel, a patented flowable choline powder launched with commercial-scale trials completed in December 2024 and global patent application filed; Premneo, a DHA emulsion for preterm infants advancing regulatory approvals in ANZ and EU; Gelphorm double emulsion DHA for UHT drinks adopted by a major USA brand; concentrated high omega-3 powders for nutraceuticals, petfood and medical foods; and probiotics in development, serving infant formula, nutraceuticals, pharmaceuticals, sports nutrition, food and beverage markets. Founded in 1988 and headquartered in Altona North, Australia, Clover operates in Australia, New Zealand, Asia including China and Japan, Europe, North America and the Americas through appointed distributors. Latest developments include record FY25 revenue of A$86 million up 38% driven by new customer growth and expansions into adult, senior and children's nutrition; Ecuador facility supplying 30% of tuna oil needs since November 2024 with high yields; debt largely repaid strengthening the balance sheet to A$8.9 million cash; FY26 1H revenue guidance of A$40-43 million with full-year expected to outperform FY25; and board changes at the November 2025 AGM featuring Graeme Billings' retirement, Dr. Simon Green's re-election and Fiona Pearse's election.